LEIDEN, NETHERLANDS--(Marketwire - March 10, 2011) - Presentations will highlight strong
antiviral activity and SVR rates together
with significant reductions in flu-like adverse events and reduced rates of
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) announces that
abstracts by its licensee Biolex Therapeutics have been accepted for
presentation on 31 March at the 46th Annual Meeting of the European
for the Study of the Liver (EASL) in Berlin, Germany.
The titles of the abstracts are included below and the complete abstracts
now available on the EASL website atwww2.kenes.com/liver-congress.
* SVRfor controlled-release interferon alpha-2b (CR2b) + ribavirin
compared to PEGylated interferon alpha-2b (PEG2b) + ribavirin in
treatment-naïve genotype-1 (G1) hepatitis C: final results from
* Timing and frequency of depression during HCV-treatment with
controlled-release-IFNa2b (CR2b) vs. PEGylated-IFNa2b (PEG2b): results
from SELECT-2, a randomized-open-label-72-week-comparison in 116
treatment-naïve patients with genotype-1 HCV
Locteron is a controlled release formulation of interferon alpha
treatment of chronic hepatitis C. Locteron combines OctoPlus' controlled
drug delivery technology PolyActive® with Biolex' interferon alpha
and is the
most advanced product in clinical development incorporating one of
proprietary drug delivery technologies. OctoPlus licensed its commercial
to Locteron exclusively to Biolex in October 2008.
Locteron is an investigational therapeutic candidate and has not been
for sale by the United States Food and Drug Administration or by
international regulatory agency.
OctoPlus is a drug delivery service company committed to the
improved pharmaceutical products that are based on OctoPlus' proprietary
delivery technologies and have fewer side effects, improved patient
and a better efficacy/safety balance than existing therapies. OctoPlus
on the development of long-acting, controlled release versions of known
therapeutics, other drugs, and vaccines on behalf of its clients.
The clinically most advanced product incorporating our technology is
Therapeutics' lead product Locteron®, a controlled release
interferon alpha for the treatment of chronic hepatitis C. OctoPlus
Locteron exclusively to Biolex in October 2008. Locteron is being
for Biolex by OctoPlus and has recently completed Phase IIb clinical
with superior clinical data versus current treatment.
In addition, OctoPlus is a leading European provider of advanced
formulation and clinical scale manufacturing services to the
biotechnology industries, with a focus on difficult-to-formulate
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol
For more information about OctoPlus, please visit our website
This document may contain certain forward-looking statements relating
business, financial performance and results of OctoPlus and the
which it operates. These statements are based on OctoPlus' current
estimates and projections, as well as its expectations of external
and events. In particular the words "expect", "anticipate",
"estimate", "project", "plan", "may", "should", "would", "will",
"believe" and similar expressions are intended to identify forward-
statements. We caution investors that a number of important factors,
inherent risks and uncertainties that such statements involve, could
actual results or outcomes to differ materially from those expressed
forward-looking statements. In the event of any inconsistency between an
version and a Dutch version of this document, the English version will
over the Dutch version.
Click here for the press release in PDF format:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE